HIMS & HERS HEALTH INC
HIMSNYSETrading Snapshot
- Day Range
- $30.11 – $30.93
- 52-Week Range
- $13.74 – $65.30
- Volume
- $5.47B
- Avg Volume
- $6.71B
- Shares Outstanding
- 231.5M
- Next Earnings
- Oct 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.37B
- Last Q Revenue
- $595M
- P/E Ratio
- —
- P/S Ratio
- 3.1x
- EPS (TTM)
- $-0.10
- Dividend Yield
- —
Why Investors Own HIMS
- ✓High-growth profile — revenue up +34.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 31% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About HIMS & HERS HEALTH INC
A company profile for HIMS & HERS HEALTH INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Wall Street Lunch: Anthropic To Watermark AI-Generated Content In EU
Anthropic's (ANTHRO) new models released in the European Union will now embed watermarks in all AI-generated and edited content.
Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26
Deutsche Bank analyst George Hill maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $25 to $26.
B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $32
B of A Securities analyst Allen Lutz maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and raises the price target from $30 to $32.
TD Cowen Maintains Hold on Hims & Hers Health, Raises Price Target to $30
TD Cowen analyst Jonna Kim maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $25 to $30.
Morgan Stanley Maintains Equal-Weight on Hims & Hers Health, Raises Price Target to $28
Morgan Stanley analyst Craig Hettenbach maintains Hims & Hers Health (NYSE:HIMS) with a Equal-Weight and raises the price target from $21 to $28.
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst
HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.